News

Victoza is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan.It is indicated as monotherapy or as an add-on to sulphonylurea (SU) in

The approval of Aloxi is based on the compelling results of a large multicenter randomized double-blind clinical trial (Protect study) conducted in Japan, which demonstrated the superiority of

The study suggested that ICT-107, which targets those antigens, may target not only the cells that make up the bulk of certain cancerous tumors, but also the CSCs

CHK1 is a key component of a biochemical pathway responsible for reducing the effectiveness of traditional cancer therapeutics such as chemotherapy. The collaboration has developed novel, potent and

LX4211, dosed as a single agent, provided improvements in glycemic control, demonstrating benefits in the primary and multiple secondary efficacy endpoints. The recently completed study was a four-week,

The Morningside fund, in the amount of $7.5m, will provide all the required funding needed for the pre-clinical and clinical development plans up to the completion of phase

ValiRx is heading the consortium to take the company’s lead GeneICE product toward human trials and commercialisation. GeneICE compounds are based on proprietary technology, designed for the long-term

Hydrochlorothiazide capsules 12.5mg is the 3,4-dihydro derivative of chlorothiazide. Its chemical name is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Each capsule contains the following inactive ingredients: colloidal silicon dioxide, corn starch, lactose

The company claims that the 44K array offers increased coverage in known stem cell and cancer associated genes to further enhance the resolution in these functionally important regions.